ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
PhaseBio nets $34M to advance Brilinta reversal agent, PAH drug
September 06, 2018PhaseBio is using its ELP platform to extend the half-life of proteins, peptides and other large molecules to create injectable drugs that can be administered less frequently. -
With two new uses kaput, AstraZeneca touts more long-term Brilinta data at ESC
August 25, 2017In a new analysis of older trial data, Brilinta showed it could cut the risk of cardiovascular death by 29% compared with placebo. -
Extended use of AstraZeneca's Brilinta reduces cardiovascular death risk
August 25, 2017New data for AstraZeneca’s blood thinner Brilinta (ticagrelor) has shown that extended use of the drug can cut the risk of heart attacks by almost a third in patients with a history of such atherothrombotic events. -
Extended treatment with Brilinta reduces risk of cardiovascular death by 29% in patients with histor
August 25, 2017AstraZeneca today announced results from a new sub-analysis of data from the Phase III PEGASUS-TIMI 54 trial demonstrating a 29% risk reduction in ...
Pharma Sources Insight January 2025
